Caisse DE Depot ET Placement DU Quebec raised its position in Boston Scientific Corporation (NYSE:BSX) by 27.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,126 shares of the medical equipment provider’s stock after acquiring an additional 4,700 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in Boston Scientific were worth $648,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of BSX. Janus Henderson Group PLC raised its holdings in shares of Boston Scientific by 22,491.6% in the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after buying an additional 38,690,577 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Boston Scientific by 405.3% in the 2nd quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock worth $294,921,000 after buying an additional 8,533,655 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Boston Scientific by 4.6% in the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after buying an additional 4,439,966 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Boston Scientific by 35,016.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after buying an additional 3,033,800 shares in the last quarter. Finally, Prudential Financial Inc. raised its holdings in shares of Boston Scientific by 149.1% in the 3rd quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock worth $138,928,000 after buying an additional 2,850,630 shares in the last quarter. 90.57% of the stock is owned by hedge funds and other institutional investors.
In other Boston Scientific news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $28.72, for a total value of $445,160.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy A. Pratt sold 11,061 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $29.24, for a total value of $323,423.64. Following the completion of the transaction, the executive vice president now owns 174,681 shares in the company, valued at $5,107,672.44. The disclosure for this sale can be found here. Insiders sold a total of 424,698 shares of company stock worth $12,273,553 over the last quarter. Corporate insiders own 0.74% of the company’s stock.
Shares of Boston Scientific Corporation (BSX) traded down $0.09 on Friday, reaching $25.62. The company’s stock had a trading volume of 10,490,100 shares, compared to its average volume of 7,061,868. The company has a market cap of $35,304.87, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 1.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific Corporation has a 52-week low of $21.03 and a 52-week high of $29.93.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company earned $0.27 EPS. equities analysts forecast that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.
A number of research firms recently weighed in on BSX. BMO Capital Markets reaffirmed a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a report on Tuesday. TheStreet cut Boston Scientific from a “b” rating to a “c+” rating in a report on Thursday, December 7th. Needham & Company LLC raised Boston Scientific from a “buy” rating to a “strong-buy” rating and raised their price target for the company from $25.04 to $32.00 in a report on Friday, December 8th. SunTrust Banks set a $33.00 price target on Boston Scientific and gave the company a “buy” rating in a report on Monday, December 4th. Finally, Cowen set a $31.00 price target on Boston Scientific and gave the company a “buy” rating in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Boston Scientific currently has a consensus rating of “Buy” and a consensus price target of $31.03.
COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/15/caisse-de-depot-et-placement-du-quebec-purchases-4700-shares-of-boston-scientific-corporation-bsx.html.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.